Citadel Advisors’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Citadel Advisors’s Portfolio SBIO Stock Details SBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-200	Closed	-$5.7K	–	14739
2025 Q1	$5.7K	Hold	200	–	–	﹤0.01%	13800
2024 Q4	$6.61K	Buy	+200	New	+$7.55K	﹤0.01%	13787
2024 Q2	–	Sell	-2,000	Closed	-$71.5K	–	15249
2024 Q1	$71.5K	Sell	2,000 -2,000	-50%	-$69.3K	﹤0.01%	11792
2023 Q4	$132K	Hold	4,000	–	–	﹤0.01%	10585
2023 Q3	$109K	Buy	4,000 +2,800	+233%	+$84.3K	﹤0.01%	10783
2023 Q2	$37.9K	Sell	1,200 -800	-40%	-$24.8K	﹤0.01%	12115
2023 Q1	$54.4K	Sell	2,000 -400	-17%	-$12.1K	﹤0.01%	12048
2022 Q4	$72.9K	Buy	+2,400	New	+$72.2K	﹤0.01%	11651
2021 Q1	–	Sell	-6,300	Closed	-$323K	–	13655
2020 Q4	$323K	Buy	+6,300	New	+$300K	﹤0.01%	8944
2019 Q2	–	Sell	-7,900	Closed	-$286K	–	9759
2019 Q1	$286K	Buy	+7,900	New	+$264K	﹤0.01%	7689
2018 Q4	–	Sell	-5,300	Closed	-$209K	–	9669
2018 Q3	$209K	Buy	+5,300	New	+$201K	﹤0.01%	8151

Other funds holding SBIO

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

CIS

Connors Investor Services Wyomissing, Pennsylvania $1.16B AUM 27.24% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

MWM

Moran Wealth Management Naples, Florida $3.67B AUM 36.71% 1-Year Est. Return

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Citadel Advisors's SBIO Position: Q2 2026 in Review

Citadel Advisors sold out of ALPS Medical Breakthroughs ETF (SBIO) in Q2 2026, closing a stake of 17,680 shares — an estimated $925K sold.

Citadel Advisors first reported a position in SBIO in Q3 2015 and held it in 34 quarters. The position peaked at $3.14M in Q4 2018. 65 funds tracked by Wall St. Rank hold SBIO as of Q2 2026.

Citadel Advisors reported no remaining ALPS Medical Breakthroughs ETF position as of Q2 2026 after selling out during the quarter.
Citadel Advisors sold 17,680 ALPS Medical Breakthroughs ETF shares in Q2 2026, an estimated $925K.
Citadel Advisors first reported a position in ALPS Medical Breakthroughs ETF in Q3 2015 and held it in 34 quarters.
Citadel Advisors's ALPS Medical Breakthroughs ETF position peaked at $3.14M in Q4 2018.
65 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.